|
"kitagawa y"的相關文件
顯示項目 1-7 / 7 (共1頁)
1
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2022-08-19T06:48:41Z |
Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
|
Kitagawa Y.; Matsumura Y.; Takazawa A.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU; Holtved E.; Xynos I.; Ahn M.-J.; Kadowaki S.; Cho B.C.; Takahashi M.; Lin C.-Y.; Chin K.; Okada M.; Kato K. |
| 臺大學術典藏 |
2021-01-28T01:06:15Z |
JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions
|
Yoshino T.; Pentheroudakis G.; Mishima S.; Overman M.J.; KUN-HUEI YEH; Baba E.; Naito Y.; Calvo F.; Saxena A.; Chen L.-T.; Takeda M.; Cervantes A.; Taniguchi H.; Yoshida K.; Kodera Y.; Kitagawa Y.; Tabernero J.; Burris H.; Douillard J.-Y. |
| 臺大學術典藏 |
2020-04-28T07:25:09Z |
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
|
Kato K.; Cho B.C.; Takahashi M.; Okada M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU; Holtved E.; Xynos I.; Kodani M.; Kitagawa Y.; Kato K.;Cho B.C.;Takahashi M.;Okada M.;Lin C.-Y.;Chin K.;Kadowaki S.;Ahn M.-J.;Hamamoto Y.;Doki Y.;Yen C.-C.;Kubota Y.;Kim S.-B.;Chih-Hung Hsu;Holtved E.;Xynos I.;Kodani M.;Kitagawa Y. |
| 國家衛生研究院 |
2020-04-06 |
JSCO/ESMO/ASCO/JSMO/TOS: International expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions
|
Yoshino, T;Pentheroudakis, G;Mishima, S;Overman, MJ;Yeh, KH;Baba, E;Naito, Y;Calvo, F;Saxena, A;Chen, LT;Takeda, M;Cervantes, A;Taniguchi, H;Yoshida, K;Kodera, Y;Kitagawa, Y;Tabernero, J;Burris, H;Douillard, JY |
| 國立成功大學 |
2019 |
Effect of First-line S-1 Plus Oxaliplatin with or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial
|
Yoshikawa, T.;Muro, K.;Shitara, K.;Oh, D.-Y.;Kang, Y.-K.;Chung, H.C.;Kudo, T.;Chin, K.;Kadowaki, S.;Hamamoto, Y.;Hironaka, S.;Yoshida, K.;Yen, C.-J.;Omuro, Y.;Bai, L.-Y.;Maeda, K.;Ozeki, A.;Yoshikawa, R.;Kitagawa, Y. |
| 國家衛生研究院 |
2016-02 |
Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer
|
Izumi, K;Mizokami, A;Lin, HP;Ho, HM;Iwamoto, H;Maolake, A;Natsagdorj, A;Kitagawa, Y;Kadono, Y;Miyamoto, H;Huang, CK;Namiki, M;Lin, WJ |
| 國家衛生研究院 |
2014-08 |
Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level
|
Izumi, K;Lin, WJ;Miyamoto, H;Huang, CK;Maolake, A;Kitagawa, Y;Kadono, Y;Konaka, H;Mizokami, A;Namiki, M |
顯示項目 1-7 / 7 (共1頁)
1
每頁顯示[10|25|50]項目
|
